Early Cytomegalovirus Reactivation in Renal Recipients Is Associated with High Levels of B Cell Maturation Antigen Transcript Expression Prior to Transplantation.
BAFF gene expression
BCMA
CMV
acute rejection
kidney transplant
plasmablast
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
22 Jun 2023
22 Jun 2023
Historique:
received:
21
04
2023
revised:
13
06
2023
accepted:
20
06
2023
medline:
17
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Cytomegalovirus (CMV) infection is the most frequent infection episode in kidney transplant (KT) recipients. Reactivation usually occurs in the first three months after transplantation and is associated with higher cellular and/or antibody-mediated rejection rates and poorer graft performance. CMV induces the expression of BAFF (B-cell-activating factor, a cytokine involved in the homeostasis of B cells), which communicates signals for survival and growth to B cells and virus-specific plasma cells via the R-BAFF (BAFF receptor), TACI (the calcium modulator, the cyclophilin ligand interactor), and BCMA (B cell maturation antigen) receptors. These molecules of the BAFF system have also been suggested as biomarkers for the development of alloantibodies and graft dysfunction. This prospective study included 30 CMV-IgG seropositive KT recipients. The expression levels of the genes BAFF-R, transmembrane activator and CAML interactor (TACI), and B cell maturation antigen (BCMA) in peripheral blood leukocytes (PBL) pre-KT were determined using qPCR. qPCR was also used to monitor CMV reactivation in the first three months following KT. The remainder of the KT recipients were classified as CMV- reactivation, and those with more than 500 copies/mL in at least one sample were classified as CMV+ reactivation. There were no discernible variations in the BAFF-R and TACI transcript expression levels. In the CMV+ group, we examined the relationship between the transcript levels and peak viremia. Peak viremia levels and BCMA transcript levels showed a strong correlation. BAFF-R and TACI expressions showed no measurable differences. In patients with early CMV reactivation, high BCMA receptor expression was associated with increased plasmablast, lymphocyte B cell class-switched levels (LBCS), and viral load. Our findings demonstrate that pre-KT BCMA transcript levels increased in KT recipients with early CMV reactivation. These transcript levels positively correlate with peak viremia and weakly with plasmablast and LBCS levels in PBLs.
Identifiants
pubmed: 37445668
pii: ijms241310491
doi: 10.3390/ijms241310491
pmc: PMC10341624
pii:
doi:
Substances chimiques
B-Cell Maturation Antigen
0
Transmembrane Activator and CAML Interactor Protein
0
B-Cell Activating Factor
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Instituto de Salud Carlos III (ISCIII)
ID : P19/01194
Organisme : European Fund of Regional Development (FEDER)
ID : "A manner to build Europe"
Références
J Immunol. 2007 Dec 1;179(11):7276-86
pubmed: 18025170
Semin Immunol. 2006 Oct;18(5):263-75
pubmed: 16914324
J Heart Lung Transplant. 2018 Aug;37(8):1001-1012
pubmed: 29754764
Am J Transplant. 2012 Oct;12(10):2754-62
pubmed: 22883025
J Clin Med. 2022 Jul 07;11(14):
pubmed: 35887720
Kidney Int. 2012 Apr;81(7):628-39
pubmed: 22297669
Transplantation. 2016 Mar;100 Suppl 3:S11-8
pubmed: 26900990
Int Immunol. 2004 Mar;16(3):467-75
pubmed: 14978020
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Immunol. 2015 Jan 15;194(2):542-52
pubmed: 25505277
Lupus. 2018 Feb;27(2):243-256
pubmed: 28659046
Br J Haematol. 2012 Sep;158(6):727-38
pubmed: 22804669
Microorganisms. 2023 Feb 11;11(2):
pubmed: 36838423
Front Med (Lausanne). 2021 Feb 17;8:547849
pubmed: 33681239
Am J Transplant. 2018 Feb;18(2):293-307
pubmed: 29243394
Clin Lab Med. 2019 Mar;39(1):15-29
pubmed: 30709503
Hum Immunol. 2018 May;79(5):380-387
pubmed: 29448053
Transplant Cell Ther. 2023 Feb;29(2):95.e1-95.e10
pubmed: 36402456
Autoimmunity. 2014 Feb;47(1):1-12
pubmed: 24245950
Am J Transplant. 2020 Aug;20(8):2173-2183
pubmed: 32356368
Arch Immunol Ther Exp (Warsz). 2022 Sep 22;70(1):21
pubmed: 36136146
J Transplant. 2010;2010:
pubmed: 20871653
Trends Microbiol. 2023 May;31(5):480-497
pubmed: 36624009
J Autoimmun. 2018 Dec;95:179-190
pubmed: 30385081
Kidney Int. 2008 Sep;74(5):664-73
pubmed: 18547992
Diagnostics (Basel). 2021 Apr 01;11(4):
pubmed: 33916199
J Heart Lung Transplant. 2017 May;36(5):529-539
pubmed: 27866926
Transplantation. 2013 Nov 27;96(10):853-9
pubmed: 23774811
J Immunol. 2010 Jul 1;185(1):717-28
pubmed: 20525884
Eur J Haematol. 2009 Aug;83(2):119-29
pubmed: 19456850
Expert Opin Ther Targets. 2016 Jul;20(7):859-67
pubmed: 26695424
Clin Exp Immunol. 2021 Feb;203(2):315-328
pubmed: 33025622
Nat Rev Immunol. 2009 Jul;9(7):491-502
pubmed: 19521398
Clin Microbiol Rev. 2017 Oct;30(4):991-1014
pubmed: 28855265
Semin Immunol. 2006 Oct;18(5):284-9
pubmed: 16931039
Cell Mol Immunol. 2008 Dec;5(6):465-70
pubmed: 19118513
Transpl Immunol. 2017 Dec;45:35-41
pubmed: 28867309
Transplantation. 2013 Aug 27;96(4):413-20
pubmed: 23842189